Human RNA Polymerase I-Driven Reverse Genetics for Influenza A Virus in Canine Cells

Suphaphiphat, Pirada; Keiner, Bjoern; Trusheim, Heidi; Crotta, Stefania; Tuccino, Annunziata Barbara; Zhang, Pu; Dormitzer, Philip R.; Mason, Peter W.; Franti, Michael

doi:10.1128/jvi.01925-09

Cited by 15 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this manner, the effect of antiviral compounds on virus replication can be determined either by FACS analysis of virus-infected cells or by plaque assay or ELISA of cell-free virus. A recent development in influenza vaccinology is the ability to grow influenza viruses in non-adherent cells that grow in suspension [41]. These cells may be very useful for determining the pharmacodynamic index for antiviral compounds for influenza viruses in the HFIM system.…”

Section: Discussionmentioning

confidence: 99%

Antiviral Pharmacodynamics in Hollow Fibre Bioreactors

McSharry

Drusano

2011

Antivir Chem Chemother

View full text Add to dashboard Cite

Pharmacodynamic investigation of antiviral compounds studies the relationship between drug exposure and the virological response. These studies are usually performed in animals and, eventually, in humans and are a very expensive proposition. To find a more efficient and less expensive method for determining pharmacodynamics of antiviral and antimicrobial compounds, the hollow fibre infection model (HFIM) system was developed to perform pharmacodynamic studies in vitro. This review covers the authors' studies on the use of in vitro hollow fibre bioreactor technologies for determining the pharmacodynamics of antiviral compounds for viruses grown in cultured cells, including HIV grown in CD4+ lymphoblastoid cells, vaccinia viruses grown in HeLa-S3 cells and influenza viruses grown in Madin-Darby canine kidney cells. Where possible, correlations between the pharmacodynamic index derived from the in vitro HFIM systems and clinical pharmacodynamic studies are made.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiviral Pharmacodynamics in Hollow Fibre Bioreactors

McSharry

Drusano

2011

Antivir Chem Chemother

View full text Add to dashboard Cite

show abstract

“…As the termini of influenza vRNAs are crucial for virus replication, plasmids carrying truncated pol1 or t7pol have been used to generate vRNAs with the exact 5 0 end, whereas pol1 terminator sequences (t1) or a hepatitis q ribozyme site has been used to generate the exact 3 0 end. Plasmids carry typical pol2 promoters (CMV and/or chicken b-actin promoters) and the polyA region bovine growth factor (aBGH), while the polyA tail is used to synthesize influenza mRNAs for viral proteins [5][6][7][8][9]. Bidirectional RG plasmids carrying all segments have been co-transfected into human embryo kidney (HEK)-293T cells to generate influenza viruses.…”

Section: Introductionmentioning

confidence: 99%

Alternative reverse genetics system for influenza viruses based on a synthesized swine 45S rRNA promoter

et al. 2017

View full text Add to dashboard Cite

We generated an alternative reverse genetics (RG) system based on a synthesized swine 45S rRNA promoter to rescue the H3N2 subtype swine influenza virus. All eight flanking segment cassettes of A/swine/ Henan/7/2010 (H3N2) were amplified with ambisense expression elements from RG plasmids. All segments were then recombined with the pHC2014 vector, which contained the synthesized swine 45S rRNA promoter (spol1) and its terminal sequence (t1) in a pcDNA3 backbone. As a result, we obtained a set of RG plasmids carrying the corresponding eight-segment cassettes. We efficiently generated the H3N2 virus after transfection into 293T/ PK15, PK15, and 293T cells. The efficiency of spol1-driven influenza virus rescue in PK15 cells was similar to that in 293T cells by titration using the human pol1 RG system. Our approach suggests that an alternative spol1-based RG system can produce influenza viruses.

show abstract

“…MDCK 33016PF is an approved certified proprietary cell line that grows efficiently in suspension in serum-free medium [43]. These cells yield a statistically higher isolation rate (89%) of H1N1pdm than allantoically inoculated eggs (66%), although HA titers of viruses isolated in MDCK 33016PF cells may be lower than those isolated in eggs after two passages [44].…”

mentioning

confidence: 99%

Flucelvax (Optaflu) for seasonal influenza

Manini

Domnich

Amicizia

et al. 2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Conventional egg-based manufacturing technology for seasonal influenza vaccines has several drawbacks, including its inflexibility, reliance on egg supplies, risk of contamination, absence of growth of some isolates and egg-adaptive viral mutations that threaten vaccine matching. To overcome these limitations, cell culture-derived vaccines have been designed, including the trivalent inactivated vaccine Flucelvax®/Optaflu® (brand names in the US/EU, respectively). Flucelvax®/Optaflu® has gained wide regulatory approval and is currently implemented in several countries. Non-clinical studies have assuaged hypothetical concerns regarding oncogenicity and use in persons allergic to dogs. Ample clinical data suggest the non-inferiority of Flucelvax®/Optaflu® to egg-based vaccines in terms of immunogenicity, safety and tolerability, and it has fulfilled American and European mandatory requirements. Although Flucelvax®/Optaflu® is currently indicated only for adults and the elderly, pediatric data indicate its good immunogenicity and safety. This paper provides an update on the clinical development of Flucelvax®/Optaflu®, its seasonal trials and available post-marketing surveillance data.

show abstract

Human RNA Polymerase I-Driven Reverse Genetics for Influenza A Virus in Canine Cells

Cited by 15 publications

References 16 publications

Antiviral Pharmacodynamics in Hollow Fibre Bioreactors

Antiviral Pharmacodynamics in Hollow Fibre Bioreactors

Alternative reverse genetics system for influenza viruses based on a synthesized swine 45S rRNA promoter

Flucelvax (Optaflu) for seasonal influenza

Contact Info

Product

Resources

About